IRCT20210519051345N11 IRCT 2022-05-12 Tabriz University of Medical Sciences Investigating In vivo Bioequivalence of Rosuvastatin Tablet In vivo Fasted-State Bioequivalence Study of Rosuvastatin 40 mg Tablet Compared to Innovator Product 2022-05-20 anticipated 24 Complete https://irct.ir/trial/60329 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Crossover, Purpose: Other, Randomization description: The order of receiving the test product or reference for each subject in each time period will be determined based on the randomization program. The randomization program will be developed using randomization software based on the number assigned to each subject. The number assigned to each subject will be based on the priority of being on the list of subjects for screening, Blinding description: In this study, Volunteers participating will be blinded to the type of product they are taking in each period (test or reference product). This means that the product will be given to the volunteers for administration outside the original packaging. Bioequivalence In the present study, no diseases will be examined and products will be administered by healthy volunteers.. Intervention 1: Intervention group: Intervention group will receive one test drug product. Blood samples will be taken from the volunteers for 48 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be measured by liquid chromatography with mass spectroscopy detector. Intervention 2: Control group: Control group will receive one reference drug product. Blood samples will be taken from the volunteers for 48 hours at the mentioned times after drug administration and the concentration of drug in blood samples will be measured by liquid chromatography with mass spectroscopy detector. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no more information.